The stock of Sarepta Therapeutics Inc (NASDAQ: SRPT) has increased by 0.28 when compared to last closing price of 36.27. Despite this, the company has experienced a -42.87% fall in its stock price over the last five trading sessions. accessnewswire.com reported 2025-05-10 that NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
Company’s 36-month beta value is 0.75.Analysts have differing opinions on the stock, with 14 analysts rating it as a “buy,” 7 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for SRPT is 92.31M, and currently, short sellers hold a 7.26% ratio of that floaft. The average trading volume of SRPT on May 13, 2025 was 2.77M shares.
SRPT’s Market Performance
The stock of Sarepta Therapeutics Inc (SRPT) has seen a -42.87% decrease in the past week, with a -27.71% drop in the past month, and a -67.74% fall in the past quarter. The volatility ratio for the week is 14.53%, and the volatility levels for the past 30 days are at 7.02% for SRPT. The simple moving average for the last 20 days is -32.67% for SRPT stock, with a simple moving average of -66.99% for the last 200 days.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with Evercore ISI repeating the rating for SRPT by listing it as a “In-line.” The predicted price for SRPT in the upcoming period, according to Evercore ISI is $50 based on the research report published on May 08, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $115. The rating they have provided for SRPT stocks is “Overweight” according to the report published on April 11th, 2025.
H.C. Wainwright gave a rating of “Neutral” to SRPT, setting the target price at $75 in the report published on April 02nd of the current year.
SRPT Trading at -46.89% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.01% of loss for the given period.
Volatility was left at 7.02%, however, over the last 30 days, the volatility rate increased by 14.53%, as shares sank -28.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -65.93% lower at present.
During the last 5 trading sessions, SRPT fell by -42.87%, which changed the moving average for the period of 200-days by -75.09% in comparison to the 20-day moving average, which settled at $54.02. In addition, Sarepta Therapeutics Inc saw -70.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Nicaise Claude, who sale 2,491 shares at the price of $99.64 back on Mar 12 ’25. After this action, Nicaise Claude now owns 27,812 shares of Sarepta Therapeutics Inc, valued at $248,203 using the latest closing price.
Nicaise Claude, the Director of Sarepta Therapeutics Inc, proposed sale 2,491 shares at $99.65 during a trade that took place back on Mar 12 ’25, which means that Nicaise Claude is holding shares at $248,226 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.83 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value -23.61, with -7.43 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.15. The debt to equity ratio resting at 0.88. The interest coverage ratio of the stock is 11.86.
Currently, EBITDA for the company is 333.06 million with net debt to EBITDA at 0.78. When we switch over and look at the enterprise to sales, we see a ratio of 2.01. The receivables turnover for the company is 2.93for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.02.
Conclusion
In a nutshell, Sarepta Therapeutics Inc (SRPT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
